Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


St. Jude Would Complete DES/CRT Trinity; Does Conor Need IP Absolution?

This article was originally published in The Gray Sheet

Executive Summary

Conor Medsystems may realize a legal benefit from Boston Scientific's newly acquired right to sublicense the use of paclitaxel on coronary stents

You may also be interested in...

Medtronic ICD Growth Rate Hiccups On “Trialing” Of St. Jude Epic

Medtronic expects to quickly return to 20%-plus growth in its ICD business with the launch of its Insync Sentry cardiac resynchronization therapy defibrillator with thoracic fluid status monitoring

Conor Medsystems Faces IP Hurdles To Reach DES Market, Plans $70 Mil. IPO

Conor Medsystems will build a direct sales force for U.S. marketing of its CoStar drug-eluting stent (DES) using proceeds from an initial public offering of up to $70 mil. in common stock

Execs On The Move: New R&D Chief Promotion At HAL Allergy; Two C-Level Appointments At Starkey

HAL Allergy Group, developer of products for allergy diagnostics and allergen immunotherapy, promoted its principal scientist to chief R&D officer; Starkey Hearing Technologies brought on new health and business development execs to expand its global footprint; and more.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts